Gastric Intestinal Metaplasia: Real Culprit or Innocent Bystander as a Precancerous Condition for Gastric Cancer?
- PMID: 37652306
- DOI: 10.1053/j.gastro.2023.08.028
Gastric Intestinal Metaplasia: Real Culprit or Innocent Bystander as a Precancerous Condition for Gastric Cancer?
Abstract
Gastric intestinal metaplasia (GIM), which denotes conversion of gastric mucosa into an intestinal phenotype, can occur in all regions of the stomach, including cardiac, fundic, and pyloric mucosa. Since the earliest description of GIM, its association with gastric cancer of the differentiated (intestinal) type has been a well-recognized concern. Many epidemiologic studies have confirmed GIM to be significantly associated with subsequent gastric cancer development. Helicobacter pylori, the principal etiologic factor for gastric cancer, plays the most important role in predisposing to GIM. Although the role of GIM in the stepwise progression model of gastric carcinogenesis (the so-called "Correa cascade") has come into question recently, we review the scientific evidence that strongly supports this long-standing model and propose a new progression model that builds on the Correa cascade. Eradication of H pylori is the most important method for preventing gastric cancer globally, but the effect of eradication on established GIM, is limited, if any. Endoscopic surveillance for GIM may, therefore, be necessary, especially when there is extensive corpus GIM. Recent advances in image-enhanced endoscopy with integrated artificial intelligence have facilitated the identification of GIM and neoplastic lesions, which will impact preventive strategies in the near future.
Keywords: Autoimmune Gastritis; Endoscopic Diagnosis; Gastric Adenoma; Gastric Atrophy; Gastric Cancer; Gastric Dysplasia; Helicobacter pylori; Intestinal Metaplasia.
Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.Gastroenterology. 2025 Feb;168(2):405-416.e1. doi: 10.1053/j.gastro.2024.11.001. Epub 2024 Dec 23. Gastroenterology. 2025. PMID: 39718517 Review.
-
The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines.Gut. 2024 Sep 9;73(10):1607-1617. doi: 10.1136/gutjnl-2024-333029. Gut. 2024. PMID: 39122364
-
Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy.Gastrointest Endosc. 2020 Jan;91(1):70-77.e1. doi: 10.1016/j.gie.2019.07.038. Epub 2019 Aug 16. Gastrointest Endosc. 2020. PMID: 31425693
-
Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting.Cleve Clin J Med. 2024 Jan 2;91(1):33-39. doi: 10.3949/ccjm.91a.23015. Cleve Clin J Med. 2024. PMID: 38167394 Review.
-
Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance.World J Gastroenterol. 2016 Jan 21;22(3):1311-20. doi: 10.3748/wjg.v22.i3.1311. World J Gastroenterol. 2016. PMID: 26811668 Free PMC article. Review.
Cited by
-
Gastric cancer risk after Helicobacter pylori eradication in gastritis and peptic ulcer: a retrospective cohort study in Japan.BMC Gastroenterol. 2025 Jul 1;25(1):463. doi: 10.1186/s12876-025-04034-3. BMC Gastroenterol. 2025. PMID: 40596880 Free PMC article.
-
Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study.Gut. 2025 May 7;74(6):884-893. doi: 10.1136/gutjnl-2024-333522. Gut. 2025. PMID: 39753334 Free PMC article.
-
Genomic analyses identify 15 susceptibility loci and reveal HDAC2, SOX2-OT, and IGF2BP2 in a naturally-occurring canine model of gastric cancer.bioRxiv [Preprint]. 2024 Aug 16:2024.08.14.604426. doi: 10.1101/2024.08.14.604426. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2025 Jun 3;122(22):e2416723122. doi: 10.1073/pnas.2416723122. PMID: 39372775 Free PMC article. Updated. Preprint.
-
Jumonji domain-containing protein 6 promotes gastric cancer progression: Modulating immune evasion through autophagy and oxidative stress pathways.Cytojournal. 2025 Jan 23;22:6. doi: 10.25259/Cytojournal_230_2024. eCollection 2025. Cytojournal. 2025. PMID: 39958885 Free PMC article.
-
MiR-3613-5p targets AQP4 to promote the progression of chronic atrophic gastritis to gastric cancer.Front Pharmacol. 2025 Apr 4;16:1523689. doi: 10.3389/fphar.2025.1523689. eCollection 2025. Front Pharmacol. 2025. PMID: 40255569 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical